| OCR Text |
Show 10 [27] W Asher Wolf, Kevin Z Huang, Raquel Durban, Zahra J Iqbal, Benjamin S Robey, Farah J Khalid, and Evan S Dellon. The six-food elimination diet for eosinophilic esophagitis increases grocery shopping cost and complexity. Dysphagia, 31(6):765– 770, Aug 2016. [28] Javier Molina-Infante, David A Katzka, and Javier P Gisbert. Review article: proton pump inhibitor therapy for suspected eosinophilic oesophagitis. Alimentary Pharmacology & Therapeutics, 37(12):1157–1164, Jun 2013. [29] Alberto Pilotto, Marilisa Franceschi, Gioacchino Leandro, Carlo Scarcelli, Luigi Piero D’Ambrosio, Francesco Paris, Vito Annese, Davide Seripa, Angelo Andriulli, and Francesco Di Mario. Comparison of four proton pump inhibitors for the shortterm treatment of esophagitis in elderly patients. World Journal of Gastroenterology, 13(33):4467–4472, Sep 2007. [30] W Asher Wolf and Evan S Dellon. Eosinophilic esophagitis and proton pump inhibitors: controversies and implications for clinical practice. Gastroenterology & Hepatology, 10(7):427–432, Jul 2014. [31] Bridget K Butz, Ting Wen, Gerald J Gleich, Glenn T Furuta, Jonathan Spergel, Eileen King, Robert E Kramer, Margaret H Collins, Emily Stucke, Colleen Mangeot, W Daniel Jackson, Molly O’Gorman, J Pablo Abonia, Scott Pentiuk, Philip E Putnam, and Marc E Rothenberg. Efficacy, dose reduction, and resistance to high-dose fluticasone in patients with eosinophilic esophagitis. Gastroenterology, 147(2):324–33.e5, Aug 2014. [32] Alex Straumann, Sebastien Conus, Lukas Degen, Cornelia Frei, Christian Bussmann, Christoph Beglinger, Alain Schoepfer, and Hans-Uwe Simon. Long-term budesonide maintenance treatment is partially effective for patients with eosinophilic esophagitis. Clinical Gastroenterology and Hepatology, 9(5):400–9.e1, May 2011. [33] Doerthe A Andreae, Matthew G Hanna, Margret S Magid, Stefano Malerba, Michael H Andreae, Emilia Bagiella, and Mirna Chehade. Swallowed fluticasone propionate is an effective long-term maintenance therapy for children with eosinophilic esophagitis. The American Journal of Gastroenterology, 111(8):1187–1197, Jun 2016. [34] Alex Straumann, Sébastien Conus, Pascale Grzonka, Hirohito Kita, G Kephart, C Bussmann, C Beglinger, David A Smith, John Patel, Michael Byrne, and H-U Simon. Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trial. Gut, 59(1):21–30, Jan 2010. [35] Amal H Assa’ad, Sandeep K Gupta, Margaret H Collins, Mike Thomson, Amy T Heath, Deborah A Smith, Teresa L Perschy, Cynthia H Jurgensen, Hector G Ortega, and Seema S Aceves. An antibody against IL-5 reduces numbers of esophageal intraepithelial eosinophils in children with eosinophilic esophagitis. Gastroenterology, 141(5):1593–1604, Nov 2011. [36] Jonathan M Spergel, Marc E Rothenberg, Margaret H Collins, Glenn T Furuta, Jonathan E Markowitz, George Fuchs, Molly A O’Gorman, Juan Pablo Abonia, James Young, Timothy Henkel, H Jeffrey Wilkins, and Chris A Liacouras. Reslizumab in |